C-21-7D12

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameC-21-7D12

Drug Alias NameC-7 biVHHanti-CD16A/anti-EGFR NK-cell engager (Lava Therapeutics/Vrije Universiteit van Amsterdam/Glycostem/Radboud Institute of Health Sciences)anti-CD16A/anti-EGFR immune-cell engager (Lava Therapeutics/Amsterdam UMC/Glycostem/Radboud University medical center)C-21-7D12

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionEpidermal growth factor receptor erbB1 modulatorsLow affinity immunoglobulin gamma Fc region receptor III-A agonists

TargetsEpidermal growth factor receptor erbB1Low affinity immunoglobulin gamma Fc region receptor III-A

Therapy Area/IndicationsColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesUniversiteit Van Amsterdam

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesLava Therapeutics BV Radboud Institute of Health Sciences Universiteit Van Amsterdam +[4]

Active IndicationsN/A

Inactive IndicationsColorectal Neoplasms

Other Information

ATC CodeN/A